Classical versus alternative macrophage activation: The Ying and the Yang in host defense against pulmonary fungal infections

Mucosal Immunology

Volumn 7, Issue 5, 2014, Pages 1023-1035

  Wager, C M Leopold ^a   Wormley, F L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ALTERNATIVE MACROPHAGE ACTIVATION; CELL ACTIVITY; CELL INFILTRATION; CLASSICAL MACROPHAGE ACTIVATION; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DNA MODIFICATION; HOST RESISTANCE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG MYCOSIS; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; NONHUMAN; PNEUMOCYSTIS; PRIORITY JOURNAL; REVIEW; HOST PATHOGEN INTERACTION; IMMUNOLOGY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASPERGILLUS FUMIGATUS; CELLULAR IMMUNITY; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CRYPTOCOCCOSIS; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HISTOPLASMOSIS; IMMUNOREGULATION; MYCOSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS MURINA; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; POLARIZATION; PULMONARY FUNGAL INFECTION; RESPIRATORY TRACT INFECTION;

HOST-PATHOGEN INTERACTIONS; HUMANS; LUNG DISEASES, FUNGAL; MACROPHAGE ACTIVATION;

CASPASE 9 INHIBITOR; EXTRACELLULAR SUPEROXIDE DISMUTASE; GAMMA INTERFERON; HISTONE 2B ANTIBODY; HISTONE ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MANNOSE RECEPTOR; RECOMBINANT INTERLEUKIN 23; RECOMBINANT PROTEIN; SALAZOSULFAPYRIDINE; SCAVENGER RECEPTOR A; SERUM AMYLOID P; STAT4 PROTEIN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 84906348057     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.65     Document Type: Review

References (196)

1. Park, SJ & Mehrad, B. Innate immunity to Aspergillus species. Clin. Microbiol. Rev. 22, 535-551 (2009).
2. Powderly, WG. Cryptococcal meningitis and AIDS. Clin. Infect. Dis. 17, 837-842 (1993).
3. Saag, MS et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 710-718 (2000).
4. van der Horst, CM et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337, 15-21 (1997).
5. Husain, S,Wagener,MM& Singh, N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7, 375-381 (2001).
6. Hardison, SE, Herrera, G, Young, ML, Hole, CR, Wozniak, KL & Wormley, FL Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J. Immunol. 189, 4060-4068 (2012).
7. Hardison, SE, Ravi, S, Wozniak, KL, Young, ML, Olszewski, MA & Wormley, FL Jr. Pulmonary infection with an interferon-gammaproducing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am. J. Pathol. 176, 774-785 (2010).
8. Segal, BH. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist 12, 7-13 (2007).
9. Dubourdeau, M et al. Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. J. Immunol. 177, 3994-4001 (2006).
10. Limper, AH, Hoyte, JS & Standing, JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J. Clin. Invest. 99, 2110-2117 (1997).
11. Brummer, E, Kethineni, N & Stevens, DA. Immunological basis for susceptibility and resistance to pulmonary blastomycosis in mouse strains. Cytokine 32, 12-19 (2005).
12. Brummer, E, Hanson, LH & Stevens, DA. Gamma-interferon activation of macrophages for killing of Paracoccidioides brasiliensis and evidence for nonoxidative mechanisms. Int. J. Immunopharmacol. 10, 945-952 (1988).
13. Brummer, E, Hanson, LH, Restrepo, A & Stevens, DA. In vivo and in vitro activation of pulmonary macrophages by IFN-gamma for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J. Immunol. 140, 2786-2789 (1988).
14. Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 11, 275-288 (2011).
15. Mosser, DM & Edwards, JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008).
16. Mantovani, A, Sica, A, Sozzani, S, Allavena, P, Vecchi, A & Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686 (2004).
17. Fels, AO & Cohn, ZA. The alveolar macrophage. J. Appl. Physiol. 60, 353-369 (1986).
18. Zaynagetdinov, R et al. Identification of myeloid cell subsets in murine lungs using flow cytometry. Am. J. Respir. Cell Mol. Biol. 49, 180-189 (2013).
19. Hussell, T & Bell, TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat. Rev. Immunol. 14, 81-93 (2014).
20. Feng, YH & Mao, H. Expression and preliminary functional analysis of Siglec- F on mouse macrophages. J. Zhejiang Univ. Sci. B 13, 386-394 (2012).
21. Kirby, AC, Coles, MC & Kaye, PM. Alveolar macrophages transport pathogens to lung draining lymph nodes. J. Immunol. 183, 1983-1989 (2009).
22. Strauss-Ayali, D, Conrad, SM & Mosser, DM. Monocyte subpopulations and their differentiation patterns during infection. J. Leukoc. Biol. 82, 244-252 (2007).
23. Shi, C & Pamer, EG. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762-774 (2011).
24. Yona, S et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91 (2013).
25. Schulz, C et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86-90 (2012).
26. Hashimoto, D et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792-804 (2013).
27. Maus, UA et al. Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L1245-L1252 (2002).
28. Gordon, S & Taylor, PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964 (2005).
29. Tsou, CL et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117, 902-909 (2007).
30. Serbina, NV& Pamer, EG.Monocyte emigration from bonemarrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7, 311-317 (2006).
31. Jia, T et al. Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J. Immunol. 180, 6846-6853 (2008).
32. Traynor, TR, Kuziel, WA, Toews, GB & Huffnagle, GB. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J. Immunol. 164, 2021-2027 (2000).
33. Kumagai, Y & Akira, S. Identification and functions of pattern-recognition receptors. J. Allergy Clin. Immunol. 125, 985-992 (2010).
34. Kawai, T & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
35. Sica, A & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012).
36. Stout, RD & Suttles, J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 76, 509-513 (2004).
37. Martinez, FO, Helming, L & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
38. Kraaij, MD et al. Human monocytes produce interferon-gamma upon stimulation with LPS. Cytokine 67, 7-12 (2014).
39. Choudhry, N, Petry, F, van Rooijen, N & McDonald, V. A protective role for interleukin 18 in interferon gamma-mediated innate immunity to Cryptosporidium parvum that is independent of natural killer cells. J. Infect. Dis. 206, 117-124 (2012).
40. Murray, PJ & Wynn, TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737 (2011).
41. Muller, M, Carter, S, Hofer, MJ & Campbell, IL. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity-a tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36, 368-387 (2010).
42. Liu, Y et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 180, 6270-6278 (2008).
43. Arnold, CE, Whyte, CS, Gordon, P, Barker, RN, Rees, AJ & Wilson, HM. A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo. Immunology 141, 96-110 (2014).
44. Ding, AH, Nathan, CF & Stuehr, DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141, 2407-2412 (1988).
45. Gantner, BN, Simmons, RM & Underhill, DM. Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J. 24, 1277-1286 (2005).
46. Underhill, DM, Rossnagle, E, Lowell, CA & Simmons, RM. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 106, 2543-2550 (2005).
47. Viriyakosol, S, Fierer, J, Brown, GD & Kirkland, TN. Innate immunity to the pathogenic fungus Coccidioides posadasii is dependent on Toll-like receptor 2 and Dectin-1. Infect. Immun. 73, 1553-1560 (2005).
48. Viriyakosol, S, Jimenez Mdel, P, Gurney, MA, Ashbaugh, ME & Fierer, J. Dectin-1 is required for resistance to coccidioidomycosis in mice. MBio 4, e00597-00512 (2013).
49. Steele, C et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 betaglucan receptor. J. Exp. Med. 198, 1677-1688 (2003).
50. Saijo, S et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 32, 681-691 (2010).
51. McDonald, JU, Rosas, M, Brown, GD, Jones, SA & Taylor, PR. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS One 7, e45781 (2012).
52. Robinson, MJ et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J. Exp. Med. 206, 2037-2051 (2009).
53. Way, EE, Chen, K & Kolls, JK. Dysregulation in lung immunity-the protective and pathologic Th17 response in infection. Eur. J. Immunol. 43, 3116-3124 (2013).
54. Korn, T, Bettelli, E, Oukka,M& Kuchroo, VK. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517 (2009).
55. Hardison, SE & Brown, GD. C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13, 817-822 (2012).
56. Drummond, RA & Brown, GD. The role of Dectin-1 in the host defence against fungal infections. Curr. Opin. Microbiol. 14, 392-399 (2011).
57. Wuthrich, M, Deepe, GS Jr & Klein, B. Adaptive immunity to fungi. Annu. Rev. Immunol. 30, 115-148 (2012).
58. Van Dyken, SJ & Locksley, RM. Interleukin-4- and interleukin-13- mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31, 317-343 (2013).
59. Gladiator, A & LeibundGut-Landmann, S. Innate lymphoid cells: new players in IL-17-mediated antifungal immunity. PLoS Pathog. 9, e1003763 (2013).
60. Mantovani, A, Biswas, SK, Galdiero, MR, Sica, A & Locati, M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229, 176-185 (2013).
61. Martinez, FO & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
62. Nelson, MP et al. IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J. Immunol. 186, 2372-2381 (2011).
63. Walker, JA & McKenzie, AN. Development and function of group 2 innate lymphoid cells. Curr. Opin. Immunol. 25, 148-155 (2013).
64. Walker, JA,Barlow, JL&McKenzie, AN. Innate lymphoid cells-how didwe miss them?. Nat. Rev. Immunol. 13, 75-87 (2013).
65. Van Dyken, SJ et al. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells. Immunity 40, 414-424 (2014).
66. Reese, TA et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447, 92-96 (2007).
67. Stein, M, Keshav, S, Harris, N & Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176, 287-292 (1992).
68. Vercelli, D. Arginase: marker, effector, or candidate gene for asthma?. J. Clin. Invest. 111, 1815-1817 (2003).
69. Meurs, H, Maarsingh, H & Zaagsma, J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol. Sci. 24, 450-455 (2003).
70. Liu, T et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J. Immunol. 173, 3425-3431 (2004).
71. Lee, CG et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73, 479-501 (2011).
72. Nio, J, Fujimoto,W, Konno, A, Kon, Y, Owhashi, M & Iwanaga, T. Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochem. Cell Biol. 121, 473-482 (2004).
73. Shaykhiev, R et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 183, 2867-2883 (2009).
74. Stenzel, W et al. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am. J. Pathol. 174, 486-496 (2009).
75. Gratchev, A et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211, 473-486 (2006).
76. Porcheray, F et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142, 481-489 (2005).
77. Stout, RD, Jiang, C, Matta, B, Tietzel, I, Watkins, SK & Suttles, J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175, 342-349 (2005).
78. Davis, MJ et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 4, e00264-00213 (2013).
79. Szabo, SJ, Sullivan, BM, Peng, SL & Glimcher, LH. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21, 713-758 (2003).
80. Hu, X et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat. Immunol. 3, 859-866 (2002).
81. Kaplan, MH, Schindler, U, Smiley, ST & Grusby, MJ. Stat6 is required for mediating responses to IL-4 and fordevelopment of Th2 cells. Immunity 4, 313-319 (1996).
82. Takeda, K, Kishimoto, T & Akira, S. STAT6: its role in interleukin 4-mediated biological functions. J. Mol. Med. 75, 317-326 (1997).
83. Takeda, K et al. Essential role of Stat6 in IL-4 signalling. Nature 380, 627-630 (1996).
84. Qualls, JE et al. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci. Signal. 3, ra62 (2010).
85. El Kasmi, KC et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 9, 1399-1406 (2008).
86. Whyte, CS et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J. Leukoc. Biol. 90, 845-854 (2011).
87. Bogdan, C, Rollinghoff,M& Diefenbach, A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 12, 64-76 (2000).
88. Modolell, M, Corraliza, IM, Link, F, Soler, G & Eichmann, K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25, 1101-1104 (1995).
89. Rutschman, R, Lang, R, Hesse, M, Ihle, JN, Wynn, TA & Murray, PJ. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J. Immunol. 166, 2173-2177 (2001).
90. Takeda, K, Kamanaka, M, Tanaka, T, Kishimoto, T & Akira, S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J. Immunol. 157, 3220-3222 (1996).
91. Muller, U et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179, 5367-5377 (2007).
92. Osterholzer, JJ et al. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am. J. Pathol. 174, 932-943 (2009).
93. Zhang, Y et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175, 2489-2500 (2009).
94. Nakamura, LT, Wu-Hsieh, BA & Howard, DH. Recombinant murine gamma interferon stimulates macrophages of the RAW cell line to inhibit intracellular growth of Histoplasma capsulatum. Infect. Immun. 62, 680-684 (1994).
95. Moreira, AP, Dias-Melicio, LA, Peracoli, MT, Calvi, SA & Victoriano de Campos Soares,AM Killing of Paracoccidioides brasiliensis yeast cells by IFN-gamma and TNF-alpha activated murine peritoneal macrophages: evidence of H(2)O (2) and NOeffector mechanisms. Mycopathologia 166, 17-23 (2008).
96. Livonesi, MC et al. Inducible nitric oxide synthase-deficient mice show exacerbated inflammatory process and high production of both Th1 and Th2 cytokines during paracoccidioidomycosis. Microbes Infect. 11, 123-132 (2009).
97. Jimenez Mdel, P, Walls, L & Fierer, J. High levels of interleukin-10 impair resistance to pulmonary coccidioidomycosis in mice in part through control of nitric oxide synthase 2 expression. Infect. Immun. 74, 3387-3395 (2006).
98. Ullmann, BD et al. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot. Cell 3, 715-723 (2004).
99. Rocco, NM, Carmen, JC & Klein, BS Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase. Infect. Immun. 79, 2385-2395 (2011).
100. Collette, JR & Lorenz, MC. Mechanisms of immune evasion in fungal pathogens. Curr. Opin. Microbiol. 14, 668-675 (2011).
101. Seider, K, Heyken, A, Luttich, A, Miramon, P & Hube, B. Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape. Curr. Opin. Microbiol. 13, 392-400 (2010).
102. Newman, SL. Cell-mediated immunity to Histoplasma capsulatum. Semin Respir. Infect. 16, 102-108 (2001).
103. Newman, SL. Macrophages in host defense against Histoplasma capsulatum. Trends Microbiol. 7, 67-71 (1999).
104. Flavia Popi, AF, Lopes, JD & Mariano, M. GP43 from Paracoccidioides brasiliensis inhibits macrophage functions. An evasion mechanism of the fungus. Cell. Immunol. 218, 87-94 (2002).
105. Moreira, AP, Dias-Melicio, LA & Soares, AM. Interleukin-10 but not transforming growth factor beta inhibits murine activated macrophages Paracoccidioides brasiliensis killing: effect on H2O2 and NO production. Cell. Immunol. 263, 196-203 (2010).
106. Gonzalez, A, Hung, CY & Cole, GT. Nitric oxide synthase activity has limited influence on the control of Coccidioides infection in mice. Microb. Pathog. 51, 161-168 (2011).
107. Gonzalez, A, Hung,CY & Cole, GT. Coccidioides releases a soluble factor that suppresses nitric oxide production by murine primary macrophages. Microb. Pathog. 50, 100-108 (2011).
108. Chinen, T, Qureshi, MH, Koguchi, Y & Kawakami, K. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFNgamma) and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin. Exp. Immunol. 115, 491-497 (1999).
109. Kawakami, K, Zhang, T, Qureshi, MH & Saito, A. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulatedwith interferon-gamma and lipopolysaccharide. Cell. Immunol. 180, 47-54 (1997).
110. Arora, S, Hernandez, Y, Erb-Downward, JR, McDonald, RA, Toews,GB& Huffnagle, GB. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174, 6346-6356 (2005).
111. Arora, S, Olszewski, MA, Tsang, TM, McDonald, RA, Toews, GB & Huffnagle, GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infect. Immun. 79, 1915-1926 (2011).
112. Xiao, G et al. Cryptococcus neoformans inhibits nitric oxide synthesis caused by CpG-oligodeoxynucleotide-stimulated macrophages in a fashion independent of capsular polysaccharides. Microbiol. Immunol. 52, 171-179 (2008).
113. Naslund, PK, Miller,WC& Granger, DL. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63, 1298-1304 (1995).
114. Lasbury, ME et al. Defective nitric oxide production by alveolar macrophages during Pneumocystis pneumonia. Am. J. Respir. Cell Mol. Biol. 44, 540-547 (2010).
115. Lee, KS et al. Differential effects of substrate-analogue inhibitors on nitric oxide synthase dimerization. Biochem. Biophys. Res. Commun. 418, 49-55 (2012).
116. Park, BJ, Wannemuehler, KA, Marston, BJ, Govender, N, Pappas, PG & Chiller, TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525-530 (2009).
117. Antinori, S. New insights into HIV/AIDS-associated cryptococcosis. ISRN AIDS 2013, 471363 (2013).
118. Shao, X, Mednick, A, Alvarez, M, van Rooijen, N, Casadevall, A & Goldman, DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175, 3244-3251 (2005).
119. Zaragoza, O, Alvarez, M, Telzak, A, Rivera, J & Casadevall, A. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect. Immun. 75, 2729-2739 (2007).
120. Aguirre, K, Havell, EA, Gibson,GW& Johnson, LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63, 1725-1731 (1995).
121. Collins, HL & Bancroft, GJ. Cytokine enhancement of complementdependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur. J. Immunol. 22, 1447-1454 (1992).
122. Flesch, IE, Schwamberger, G & Kaufmann, SH. Fungicidal activity of IFNgamma- activated macrophages. Extracellular killing of Cryptococcus neoformans. J. Immunol. 142, 3219-3224 (1989).
123. Huffnagle, GB & Lipscomb, MF. Cells and cytokines in pulmonary cryptococcosis. Res. Immunol. 149, 387-396. discussion 512-384 (1998).
124. Levitz, SM & DiBenedetto, DJ. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect. Immun. 56, 2544-2551 (1988).
125. Kawakami, K, Tohyama, M, Xie, Q & Saito, A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol 104, 208-214 (1996).
126. Antachopoulos, C & Walsh, TJ. Immunotherapy of Cryptococcus infections. Clin. Microbiol. Infect. 18, 126-133 (2012).
127. Chen, GH, McNamara, DA, Hernandez, Y, Huffnagle, GB, Toews, GB & Olszewski, MA. Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect. Immun. 76, 2379-2391 (2008).
128. Huffnagle, GB, Boyd, MB, Street, NE & Lipscomb, MF. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160, 2393-2400 (1998).
129. Milam, JE, Herring-Palmer, AC, Pandrangi, R, McDonald, RA, Huffnagle, GB & Toews, GB. Modulation of the pulmonary type 2 T-cell response to Cryptococcus neoformans by intratracheal delivery of a tumor necrosis factor alpha-expressing adenoviral vector. Infect. Immun. 75, 4951-4958 (2007).
130. Zhang, Y et al. TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs. Am. J. Pathol. 177, 754-765 (2010).
131. Johnston, SA & May, RC. Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen. Cell Microbiol. 15, 403-411 (2013).
132. Muller, U et al. Abrogation of IL-4 receptor-alpha-dependent alternatively activated macrophages is sufficient to confer resistance against pulmonary cryptococcosis despite an ongoing Th2 response. Int. Immunol. 25, 456-470 (2013).
133. Huffnagle, GB, Yates, JL & Lipscomb, MF. Immunity to a pulmonary Cryptococcus neoformans infection requires both Cd4+ and Cd8+ T-cells. J. Exp. Med. 173, 793-800 (1991).
134. van de Veerdonk, FL, Kullberg, BJ, van der Meer, JW, Gow, NA & Netea, MG. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr. Opin. Microbiol. 11, 305-312 (2008).
135. Biondo, C et al. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur. J. Immunol. 35, 870-878 (2005).
136. Nakamura, K et al. Limited contribution of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans. FEMS Immunol Med. Microbiol. 47, 148-154 (2006).
137. Yauch, LE, Mansour, MK, Shoham, S, Rottman, JB & Levitz, SM. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect. Immun. 72, 5373-5382 (2004).
138. Bellocchio, S et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. 172, 3059-3069 (2004).
139. Wagner, H. The immunobiology of the TLR9 subfamily. Trends Immunol. 25, 381-386 (2004).
140. Krieg, AM. CpG motifs: the active ingredient in bacterial extracts?. Nat. Med. 9, 831-835 (2003).
141. Nakamura, K et al. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J. Immunol. 180, 4067-4074 (2008).
142. Rodrigues, ML et al. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot. Cell 7, 58-67 (2008).
143. Young, M, Macias, S, Thomas, D & Wormley, FL Jr. A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics 9, 2578-2588 (2009).
144. Chaturvedi, AK, Weintraub, ST, Lopez-Ribot, JL & Wormley, FL Jr. Identification and characterization of cryptococcus neoformans protein fractions that induce protective immune responses. Proteomics 13, 3429-3441 (2013).
145. Areschoug, T & Gordon, S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell Microbiol. 11, 1160-1169 (2009).
146. Means, TK et al. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med. 206, 637-653 (2009).
147. Qiu, Y et al. Scavenger receptor A modulates the immune response to pulmonary Cryptococcus neoformans infection. J. Immunol. 191, 238-248 (2013).
148. Wormley, FL Jr, Perfect, JR, Steele, C & Cox, GM. Protection against cryptococcosis by using a murine gamma interferonproducing Cryptococcus neoformans strain. Infect. Immun. 75, 1453-1462 (2007).
149. Wozniak, KL et al. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4, e6854 (2009).
150. Yale, SH & Limper, AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin. Proc. 71, 5-13 (1996).
151. Mansharamani, NG, Garland, R, Delaney, D & Koziel, H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118, 704-711 (2000).
152. Morris, A, Wachter, RM, Luce, J, Turner, J & Huang, L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 17, 73-80 (2003).
153. Radhi, S, Alexander, T, Ukwu, M, Saleh, S & Morris, A. Outcome of HIVassociated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect. Dis. 8, 118 (2008).
154. Arozullah, AM et al. A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era. Am. J. Respir. Crit. Care Med. 161 (4 Pt 1), 1081-1086 (2000).
155. Mansharamani, NG, Balachandran, D, Vernovsky, I, Garland, R & Koziel, H. Peripheral blood CD4+T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118, 712-720 (2000).
156. Masur, H et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 111, 223-231 (1989).
157. Phair, J,Munoz, A, Detels, R, Kaslow, R, Rinaldo, C & Saah, A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N. Engl. J. Med. 322, 161-165 (1990).
158. Harmsen, AG, Chen, W & Gigliotti, F. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect. Immun. 63, 2391-2395 (1995).
159. Kolls, JK et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J. Immunol. 162, 2890-2894 (1999).
160. Harmsen, AG & Stankiewicz, M. Tcells are not sufficient for resistance to Pneumocystis carinii pneumonia in mice. J. Protozool. 38, 44S-45S (1991).
161. Vassallo, R, Thomas, CF Jr, Vuk-Pavlovic, Z & Limper, AH. Alveolar macrophage interactions with Pneumocystis carinii. J. Lab. Clin. Med. 133, 535-540 (1999).
162. Von Behren, LA & Pesanti, EL. Uptake and degradation of Pneumocystis carinii by macrophages in vitro. Am. Rev. Respir. Dis. 118, 1051-1059 (1978).
163. Lasbury, ME, Durant, PJ, Ray, CA, Tschang, D, Schwendener, R & Lee, CH. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J. Immunol. 176, 6443-6453 (2006).
164. Wang, J, Gigliotti, F, Bhagwat, SP, George, TC & Wright, TW. Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia. PLoS Pathogens 6, 8 e1001058 (2010).
165. Lasbury, ME, Durant, PJ, Bartlett, MS, Smith, JW& Lee, CH. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Clin. Diagn. Lab. Immunol. 10, 293-302 (2003).
166. Lasbury, ME, Merali, S, Durant, PJ, Tschang, D, Ray, CA & Lee, CH. Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J. Biol. Chem. 282, 11009-11020 (2007).
167. Willment, JA & Brown, GD. C-type lectin receptors in antifungal immunity. Trends Microbiol. 16, 27-32 (2008).
168. Ezekowitz, RA et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 351, 155-158 (1991).
169. Koziel, H, Li, X, Armstrong, MY, Richards, FF & Rose, RM. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. Am. J. Respir. Cell Mol. Biol. 23, 452-459 (2000).
170. Wright, TW, Johnston, CJ, Harmsen, AG & Finkelstein, JN. Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. Am. J. Respir. Cell Mol. Biol. 17, 491-500 (1997).
171. Zhang, J et al. Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro. J. Leukoc. Biol. 78, 665-674 (2005).
172. Swain, SD, Lee, SJ, Nussenzweig, MC & Harmsen, AG. Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo. Infect. Immun. 71, 6213-6221 (2003).
173. Nelson, MP,Metz, AE, Li, S, Lowell, CA & Steele, C. The absence of Hck, Fgr, and Lyn tyrosine kinases augments lung innate immune responses to Pneumocystis murina. Infect. Immun. 77, 1790-1797 (2009).
174. Schmitz, J et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
175. Kurowska-Stolarska, M et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6477 (2009).
176. Kim, HY et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J. Allergy Clin. Immunol. 129, 216-227. e211-216 (2012).
177. Mjosberg, JM et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12, 1055-1062 (2011).
178. Imai, T et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activationregulated chemokine and macrophage-derived chemokine. Int. Immunol. 11, 81-88 (1999).
179. Flaczyk, A, Duerr, CU, Shourian, M, Lafferty, EI, Fritz, JH & Qureshi, ST. IL-33 signaling regulates innate and adaptive immunity to Cryptococcus neoformans. J. Immunol. 191, 2503-2513 (2013).
180. Thieu, VT et al. Signal transducer and activator of transcription 4 is
181. Kaplan, MH, Sun, YL, Hoey, T & Grusby, MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382, 174-177 (1996).
182. Myers, RC, Dunaway, CW, Nelson, MP, Trevor, JL, Morris, A & Steele, C. STAT4-dependent and -independent Th2 responses correlate with protective immunity against lung infection with Pneumocystis murina. J. Immunol. 190, 6287-6294 (2013).
183. Liew, FY, Pitman, NI & McInnes, IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
184. Brookes, MJ & Green, JR. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64, 1069-1089 (2004).
185. Plosker, GL & Croom, KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65, 1825-1849 (2005).
186. Liptay, S, Bachem, M, Hacker, G, Adler, G, Debatin, KM & Schmid, RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br. J. Pharmacol. 128, 1361-1369 (1999).
187. Weber, CK, Liptay,S,Wirth, T, Adler,G&Schmid, RM. Suppression of NFkappaB activity by sulfasalazine ismediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119, 1209-1218 (2000).
188. Guiducci, C, Vicari, AP, Sangaletti, S, Trinchieri, G & Colombo, MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005).
189. Hagemann, T et al. & quot;Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 1261-1268 (2008).
190. Duluc, D et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumorassociated macrophages. Int. J. Cancer 125, 367-373 (2009).
191. Rodrigues, AP, Carvalho, AS, Santos, AS, Alves, CN, do Nascimento, JL & Silva, EO. Kojic acid, a secondary metabolite from Aspergillus sp., acts as an inducer of macrophage activation. Cell Biol. Int. 35, 335-343 (2011).
192. Moreira, AP et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J. Allergy Clin. Immunol. 126, 712-721. e717 (2010).
193. Dan, JM, Kelly, RM, Lee,CK& Levitz, SM. Role of themannose receptor in a murine model of Cryptococcus neoformans infection. Infect. Immun. 76, 2362-2367 (2008).
194. Nosanchuk, JD, Steenbergen, JN, Shi, L, Deepe, GS Jr & Casadevall, A. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J. Clin. Invest. 112, 1164-1175 (2003).
195. Shi, L et al. A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot. Cell 7, 1109-1117 (2008).
196. Youseff, BH, Holbrook, ED, Smolnycki, KA & Rappleye, CA. Extracellular superoxide dismutase protects Histoplasma yeast cells from hostderived oxidative stress. PLoS Pathog. 8, e1002713 (2012).